Drugs / Imgatuzumab
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01702714 | Jul 2014 → Feb 2016 | non-small cell lung carcinoma | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 1 | NCT01046266 | Nov 2009 → Jun 2012 | head and neck squamous cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00721266 | Jun 2008 → Jun 2011 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04985825 | Dec 2021 → Aug 2022 | skin squamous cell carcinoma | Pega-One S.A.S. | Withdrawn | No outcome recorded |
| Phase 2 | NCT01326000 | Apr 2011 → Dec 2013 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01185847 | Nov 2010 → Sep 2012 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | imgatuzumab | “glycoengineered imgatuzumab (GA201; 700 or 1400 mg)” PMID 28950289 ↗ Nov 2017 |
| Known as | GA201 | “Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor,...” PMID 21900113 ↗ Sep 20111“glycoengineered imgatuzumab (GA201; 700 or 1400 mg)” PMID 28950289 ↗ Nov 2017 |
| Known as | HUMA-B | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109389 ↗ |
| Known as | HuMAB<EGFR> | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109389 ↗ |
| Known as | RG7160 | “Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor,...” PMID 21900113 ↗ Sep 2011 |
| Known as | RO5083945 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01046266 ↗ |
| Action | Inhibit | “anti-epidermal growth factor receptor (EGFR)” PMID 21900113 ↗ Sep 2011 |
| Modality | Monoclonal antibody | “RG7160 (GA201), a humanized and glycoengineered immunoglobulin G(1) anti-epidermal growth factor receptor (EGFR) monoclonal antibody with enhanced antibody-dependent...” PMID 21900113 ↗ Sep 2011 |
| Route | Intravenous | “Administered iv, either weekly, every 2 weeks or every 3 weeks” NCT00721266 ↗ |
| Target | EGFR | “anti-epidermal growth factor receptor (EGFR) monoclonal antibody” PMID 21900113 ↗ Sep 2011 |
| Target | FCGR3A | “Low affinity immunoglobulin gamma Fc region receptor III-A cross-linking agent” CHEMBL2109389 ↗ |